Morgan Stanley’s $21 target on MPLT

MPLT Maplight Therapeutics Inc

$9.9 → $21 (+112%) by Jul 2027

Equalweight · lowers · said Jul 27, 2026 · 12-month default horizon

Open: judged on the close on Jul 27, 2027

The article this target came from

Morgan Stanley downgrades MapLight Therapeutics stock rating on trial results

Investing.com · Jul 27, 2026

Morgan Stanley downgraded MapLight Therapeutics (NASDAQ:MPLT) to Equalweight from Overweight and lowered its price target to $21.00 from $34.00.

Morgan Stanley’s track record → Maplight Therapeutics Inc →

A fact about what Morgan Stanley published, as reported by Investing.com, not a recommendation from Dalsna Finance; Morgan Stanley is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.